Gilder Gagnon Howe & Co’s NewAmsterdam Pharma NAMS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.59M	Sell	224,070 -17,405	-7%	-$574K	0.08%	147
2026 Q1	$7.73M	Sell	241,475 -7,053	-3%	-$230K	0.09%	125
2025 Q4	$8.72M	Buy	248,528 +212,144	+583%	+$7.72M	0.09%	123
2025 Q3	$1.03M	Buy	+36,384	New	+$872K	0.01%	219
2025 Q2	–	Sell	-29,569	Closed	-$605K	–	249
2025 Q1	$605K	Sell	29,569 -302	-1%	-$6.71K	0.01%	205
2024 Q4	$768K	Buy	29,871 +5,949	+25%	+$126K	0.01%	221
2024 Q3	$397K	Sell	23,922 -463	-2%	-$8.01K	﹤0.01%	238
2024 Q2	$468K	Sell	24,385 -81	-0.3%	-$1.63K	0.01%	235
2024 Q1	$579K	Buy	+24,466	New	+$497K	0.01%	237

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Gilder Gagnon Howe & Co's NAMS Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its NewAmsterdam Pharma (NAMS) stake by 7.2% in Q2 2026, selling an estimated $574K and leaving 224,070 shares worth $7.59M. The position accounts for 0.08% of the portfolio, ranked #147.

Gilder Gagnon Howe & Co first reported a position in NAMS in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.72M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Gilder Gagnon Howe & Co held 224,070 shares of NewAmsterdam Pharma worth $7.59M as of Q2 2026.
Gilder Gagnon Howe & Co sold 17,405 NewAmsterdam Pharma shares in Q2 2026, an estimated $574K.
NewAmsterdam Pharma made up 0.08% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #147 holding.
Gilder Gagnon Howe & Co first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 9 quarters since.
Gilder Gagnon Howe & Co's NewAmsterdam Pharma position peaked at $8.72M in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.